128 related articles for article (PubMed ID: 28653286)
1. User input in iterative design for prevention product development: leveraging interdisciplinary methods to optimize effectiveness.
Guthrie KM; Rosen RK; Vargas SE; Guillen M; Steger AL; Getz ML; Smith KA; Ramirez JJ; Kojic EM
Drug Deliv Transl Res; 2017 Oct; 7(5):761-770. PubMed ID: 28653286
[TBL] [Abstract][Full Text] [Related]
2. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
[TBL] [Abstract][Full Text] [Related]
3. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.
Morrow KM; Fava JL; Rosen RK; Vargas S; Shaw JG; Kojic EM; Kiser PF; Friend DR; Katz DF;
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):78-91. PubMed ID: 24180360
[TBL] [Abstract][Full Text] [Related]
4. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.
Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF
AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455
[TBL] [Abstract][Full Text] [Related]
5. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.
Guthrie KM; Rohan L; Rosen RK; Vargas SE; Shaw JG; Katz D; Kojic EM; Ham AS; Friend D; Buckheit KW; Buckheit RW
Pharm Dev Technol; 2018 Mar; 23(3):311-314. PubMed ID: 28592183
[TBL] [Abstract][Full Text] [Related]
6. The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.
Guthrie KM; Fava JL; Vargas SE; Rosen RK; Shaw JG; Kojic EM; Ham AS; Rohan LC; Katz D; Panameño A; Colleran C; Friend DF; Buckheit KW; Buckheit RW
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1059-1070. PubMed ID: 32988214
[TBL] [Abstract][Full Text] [Related]
7. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
[TBL] [Abstract][Full Text] [Related]
8. Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning.
Lin AH; Breger TL; Barnhart M; Kim A; Vangsgaard C; Harris E
J Int AIDS Soc; 2014; 17(3 Suppl 2):19162. PubMed ID: 25224619
[TBL] [Abstract][Full Text] [Related]
9. Electrospun fibers for vaginal anti-HIV drug delivery.
Blakney AK; Ball C; Krogstad EA; Woodrow KA
Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
[TBL] [Abstract][Full Text] [Related]
10. The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development.
Morrow Guthrie K; Vargas S; Shaw JG; Rosen RK; van den Berg JJ; Kiser PF; Buckheit K; Bregman D; Thompson L; Jensen K; Johnson T; Buckheit RW
PLoS One; 2015; 10(12):e0145642. PubMed ID: 26695431
[TBL] [Abstract][Full Text] [Related]
11. Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel.
Brady M; Manning J
Antiviral Res; 2013 Dec; 100 Suppl():S25-31. PubMed ID: 24188700
[TBL] [Abstract][Full Text] [Related]
12. Non-Antiretroviral Microbicides for HIV Prevention.
Scott Y; Dezzutti CS
AIDS Rev; 2016; 18(3):145-150. PubMed ID: 27438574
[TBL] [Abstract][Full Text] [Related]
13. Microbicides for HIV prevention: reality or hope?
McGowan I
Curr Opin Infect Dis; 2010 Feb; 23(1):26-31. PubMed ID: 19935418
[TBL] [Abstract][Full Text] [Related]
14. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
Woodsong C; Holt JD
Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
[TBL] [Abstract][Full Text] [Related]
15. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
Gaym A
Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
[TBL] [Abstract][Full Text] [Related]
16. New research finds HIV can be killed with bee venom.
Kouros N
Monash Bioeth Rev; 2013 Sep; 31(2):4. PubMed ID: 24844052
[No Abstract] [Full Text] [Related]
17. Assessing the potential of the Woman's Condom for vaginal drug delivery.
Kramzer LF; Cohen J; Schubert J; Dezzutti CS; Moncla BJ; Friend D; Rohan LC
Contraception; 2015 Sep; 92(3):254-60. PubMed ID: 25998936
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Microbicides: when, how and why care now? Everything you need to know about this prevention product.
Forbes A
Posit Aware; 2005; 16(6):19-21. PubMed ID: 16335463
[No Abstract] [Full Text] [Related]
20. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
